Citius Oncology

Citius Oncology EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Citius Oncology (CTOR) as of Nov 22, 2026 is -23.52 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -20.57 M USD — a change of 14.34% (lower).

EBITDA

-23.52 MUSD

YoY

14.34%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Citius Oncology is 2025 -23.52 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Citius Oncology was 2024 -20.57 M USD. It decreases by 14.34% lower compared to the previous year.

The Citius Oncology EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2022
-9.71 M USD
Jan 1, 2023
-12.12 M USD
Jan 1, 2024
-20.57 M USD
Jan 1, 2025
-23.52 M USD
The Citius Oncology EBITDA history
YEAREBITDAYoY
-23.52 MUSD+14.34%
-20.57 MUSD+69.72%
-12.12 MUSD+24.79%
-9.71 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Citius Oncology Stock analysis

What does Citius Oncology do? Citius Oncology, Inc. develops and commercializes targeted oncology therapies, with its lead product candidate LYMPHIR for treating persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. LYMPHIR is an engineered IL-2 diphtheria toxin fusion protein that targets IL-2 receptors on cancer cells, inhibiting protein synthesis and causing cell death. The company focuses on relapsed or refractory cutaneous T-cell lymphoma (CTCL) patients after at least one prior systemic therapy, with the product indicated for Stage I-III disease. Citius Oncology, Inc. is a pharmaceutical company engaged in developing and commercializing targeted oncology therapies, with LYMPHIR as its primary product. The company's lead candidate targets CTCL, a rare non-Hodgkin lymphoma, and is designed for patients who have failed prior systemic treatments. The therapeutic mechanism involves binding to IL-2 receptors, delivering diphtheria toxin fragments to inhibit protein synthesis within cancer cells. The company's commercial strategy centers on LYMPHIR, which is positioned for relapsed or refractory CTCL patients requiring additional treatment options. LYMPHIR's mechanism of action specifically targets IL-2 receptors on cancer cells, leading to cell death through inhibition of protein synthesis. This targeted approach differentiates the product in the oncology therapy market for rare lymphoma subtypes. Citius Oncology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Citius Oncology stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Citius Oncology is -23.52 M USD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Citius Oncology changed from -20.57 M USD to -23.52 M USD, representing a 14.34% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Citius Oncology since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Citius Oncology historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Citius Oncology

All Key Metrics — Citius Oncology